check_circleStudy Completed
Relapsing-Remitting Multiple Sclerosis
Bayer Identifier:
14543
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Injection management with Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Trial purpose
Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron. The Personal digital assistant PDA functions as an electronic diary and as an injection reminder.
Key Participants Requirements
Sex
BothAge
18 - N/ATrial summary
Enrollment Goal
702Trial Dates
May 2009 - August 2014Phase
N/ACould I Receive a placebo
NoProducts
Betaseron (Interferon beta-1b, BAY86-5046)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Germany |
Primary Outcome
- Drop out rate over 2 yearsdate_rangeTime Frame:24 monthsenhanced_encryptionNoSafety Issue:
Secondary Outcome
- Disability statusdate_rangeTime Frame:After 3, 6, 12 and 24 monthsenhanced_encryptionNoSafety Issue:
- Grade of depressivenessdate_rangeTime Frame:After 3, 6, 12 and 24 monthsenhanced_encryptionNoSafety Issue:
- Grade of fatiguedate_rangeTime Frame:After 3, 6, 12 and 24 monthsenhanced_encryptionNoSafety Issue:
- Quality of lifedate_rangeTime Frame:After 3, 6, 12 and 24 monthsenhanced_encryptionNoSafety Issue:
- Cognitive statusdate_rangeTime Frame:After 12 and 24 monthsenhanced_encryptionNoSafety Issue:
- Injection regularitydate_rangeTime Frame:After 3, 6, 12 and 24 monthsenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A